Qiagen has announced the completion of its takeover of fellow life sciences company Cellestis, which was originally announced in April 2011.
The transaction has been finalised following approval by Cellestis' shareholders and the relevant courts, with the firm now becoming a fully consolidated subsidiary of the Qiagen group.
Cellestis is the developer of QuantiFERON technology, an early disease detection technology innovation that is expected to be highly complementary to Qiagen's molecular diagnostics portfolio.
Products include QuantiFERON-TB Gold, a leading test for detection of latent tuberculosis, while the cytomegalovirus monitoring system QuantiFERON-CMV is in the early stages of commercialisation.
Peer Schatz, chief executive officer of Qiagen, said: "We are pleased to have completed the transaction and will now initiate the integration process."
Last month, the company entered into a new collaboration with Pfizer on the development of a new diagnostic tool, for use in conjunction with an investigational therapy for non-small cell lung cancer.See all the latest jobs in Science